Neuroplasticity, BDNF, and Neurotrophic Deficits in Depression

The hypothesis and why it is the hub

Of all the etiological models in this series, the neuroplasticity hypothesis occupies a special position: it is less a competing cause than the final common pathway through which the others produce depression, and the common endpoint on which every effective antidepressant — monoaminergic, glutamatergic, somatic — appears to act. The neurotrophic hypothesis of depression (articulated most influentially by Ronald Duman and Lisa Monteggia) holds that depression results from impaired neuroplasticity — a deficit in the brain's capacity to form, strengthen, remodel, and maintain synaptic connections — driven substantially by a deficiency in neurotrophic signaling, with brain-derived neurotrophic factor (BDNF) as the central molecule. On this view, chronic stress and the other insults catalogued in this series degrade the structural and functional plasticity of mood-regulating circuits (especially the hippocampus and prefrontal cortex), and antidepressant treatments work by restoring it.

This matters more than any single mechanism because it reframes the entire field. Where the chemical-imbalance model asked "which neurotransmitter is low," the plasticity model asks "why has the brain lost its capacity to adapt, and how do we restore it" — a question that accommodates the slow onset of antidepressants, the rapid action of ketamine, the convergence of disparate treatments on a shared endpoint, and the integration of the inflammatory, metabolic, mitochondrial, stress, and other mechanisms into a single coherent picture. The neuroplasticity hypothesis is, in effect, where all the roads in this series meet.

The honest framing: impaired neuroplasticity is the best candidate for a unifying mechanism of depression and antidepressant action, supported by convergent structural, molecular, and treatment evidence — though "plasticity" is a broad concept that risks explaining everything and therefore nothing if stated too loosely, and the precise causal sequence in humans remains incompletely resolved.

The evidence

Structural changes — the brain remodels in depression. Among the most replicated findings in biological psychiatry: depression is associated with reduced hippocampal volume (correlating with illness duration and untreated time), prefrontal cortical atrophy, and, at the cellular level (from animal models and post-mortem human tissue), dendritic atrophy, loss of dendritic spines and synapses, reduced glial cell numbers, and suppressed hippocampal neurogenesis. Chronic stress reliably produces these same changes in animals — dendritic retraction and spine loss in hippocampus and prefrontal cortex (alongside dendritic hypertrophy in the amygdala) — providing a structural signature of the plasticity deficit.

BDNF — reduced in depression, restored by treatment. BDNF is reduced in the blood and (post-mortem) brain of depressed patients, particularly in the hippocampus; it rises with antidepressant treatment; and the magnitude tracks clinical response. The Val66Met BDNF polymorphism (which impairs activity-dependent BDNF release) is associated, in interaction with stress, with depression vulnerability and with reduced hippocampal volume — genetic support for BDNF's causal role.

Neurogenesis and the antidepressant requirement. Adult hippocampal neurogenesis is suppressed by stress and stimulated by antidepressants — and, in a landmark finding (Santarelli and colleagues), blocking neurogenesis abolishes the behavioral effects of antidepressants in mice, suggesting that, at least in animal models, neurogenesis is required for antidepressant action. (The translation to humans, where adult neurogenesis is debated, is less certain — a real caveat.)

The treatment convergence. The strongest evidence is that every effective antidepressant modality converges on enhanced plasticity: SSRIs/SNRIs slowly increase BDNF and plasticity over weeks (matching their delayed onset); ketamine rapidly induces synaptogenesis via the glutamate-AMPA-BDNF-mTOR cascade (matching its rapid onset); electroconvulsive therapy robustly increases BDNF and neurogenesis; exercise increases BDNF; even psychotherapy is associated with circuit changes. Disparate treatments reaching the same plasticity endpoint is the signature of a final common pathway.

The mechanisms

BDNF and neurotrophic signaling. BDNF, acting through its TrkB receptor, promotes neuronal survival, dendritic growth, synaptogenesis, synaptic strengthening (long-term potentiation), and neurogenesis — it is, functionally, the brain's principal pro-plasticity, pro-growth signal in mood-relevant circuits. Reduced BDNF/TrkB signaling means a brain less able to form and maintain the synaptic connections that healthy mood regulation requires.

How stress impairs plasticity. Chronic stress, via glucocorticoids (the HPA document), suppresses BDNF, retracts dendrites, eliminates synapses, and inhibits neurogenesis in the hippocampus and prefrontal cortex — degrading precisely the circuits that regulate mood and that provide negative feedback on the stress axis. The result is a less adaptable, less resilient brain stuck in maladaptive patterns.

The circuit consequence. Loss of synaptic connectivity in prefrontal-limbic circuits impairs the top-down regulation of emotion (weakened prefrontal control), while the amygdala, undergoing the opposite (hypertrophic) remodeling, becomes hyperreactive — shifting the brain toward the negative-bias, rumination-prone, poorly-regulated state of depression.

Castrén's network/critical-period reframing. Eero Castrén's influential refinement: antidepressants (and ketamine, and psychedelics) do not directly "improve mood" but reopen a state of heightened plasticity — a critical-period-like window — in which the brain becomes more modifiable by experience. On this view, the drug renders circuits plastic; whether they reorganize toward health depends on the environmental and psychological input during the open window. This elegantly explains why antidepressants work better combined with psychotherapy and a supportive environment (the plasticity needs healthy input to act on), and reframes plasticity not as intrinsically therapeutic but as permissive of change.

The convergence: why this is the final common pathway

This document is the hub because nearly every other mechanism in the series acts, in part, by impairing neuroplasticity:

• HPA-axis dysregulation — glucocorticoids suppress BDNF and damage the hippocampus (the most direct route).
• Inflammation — cytokines suppress BDNF, impair neurogenesis, and (via the kynurenine pathway) generate neurotoxic, plasticity-impairing metabolites.
• Metabolic dysfunction — insulin resistance impairs the brain's plasticity-supporting signaling and energy supply.
• Mitochondrial dysfunction — synaptic plasticity is bioenergetically expensive; energy failure impairs it.
• Oxidative stress — damages the neurons and synapses plasticity depends on.
• Sleep disruption — sleep is essential for synaptic homeostasis and consolidation.
• Hormonal disturbances — estrogen, thyroid hormone, and testosterone all promote BDNF and plasticity.
• Glutamatergic dysfunction — excitotoxicity damages synapses; the glutamate system is the substrate of plasticity itself.

These are not eight separate roads to depression but, substantially, eight routes to a single endpoint: a brain that has lost its capacity to adapt. And on the treatment side, the convergence is equally striking — antidepressants, ketamine, ECT, exercise, and psychotherapy all enhance plasticity. This is why the neuroplasticity hypothesis is the integrating framework of the entire series: it is the cellular and circuit-level common denominator beneath the diverse upstream causes and the diverse effective treatments.

Treatment implications

The plasticity framework reorganizes treatment thinking:

• All effective antidepressants are, at bottom, pro-plasticity agents — and the search for better, faster ones (the rapid-acting glutamatergic and psychedelic agents) is explicitly a search for more direct plasticity induction (the "psychoplastogen" concept).
• Exercise is a potent, mechanistically-grounded BDNF/plasticity enhancer and a genuine antidepressant.
• Combination with psychotherapy and environmental change is not adjunctive but central — the plasticity opened by medication needs healthy input to act on (Castrén's reframing).
• The "open window" model suggests timing matters — psychosocial intervention during periods of treatment-induced plasticity may be especially effective.
• Addressing the upstream impairers of plasticity (stress, inflammation, metabolic dysfunction, sleep) supports the substrate that treatments act on.

Caveats and what we don't know

• "Plasticity" is a broad, almost capacious concept — broad enough to risk explaining everything and therefore lacking specificity; rigor requires specifying which plasticity, where, and how.
• Adult human hippocampal neurogenesis is debated — the rodent neurogenesis-requirement findings may not translate cleanly to humans.
• BDNF as a peripheral biomarker is imperfect — blood BDNF is an indirect and noisy proxy for brain BDNF.
• Causality vs. consequence — whether reduced plasticity causes depression or partly results from it (and from its behavioral consequences) is not fully resolved; likely bidirectional.
• Not a complete account — plasticity deficits explain much of the convergence but do not, alone, explain why a given person becomes depressed, the specificity of symptoms, or the full heterogeneity.

The bottom line

Impaired neuroplasticity — driven by neurotrophic (BDNF) deficiency and manifest as dendritic atrophy, synaptic and glial loss, suppressed neurogenesis, and reduced hippocampal and prefrontal volume — is the strongest candidate for a final common pathway in depression, and the integrating framework of this entire series. It is supported by convergent evidence: the replicated structural changes, the BDNF reductions that reverse with treatment, the (animal) neurogenesis requirement for antidepressant action, and — most tellingly — the convergence of every effective treatment, from SSRIs to ketamine to ECT to exercise, on enhanced plasticity. Its deepest significance is unifying: the diverse upstream causes in this series — stress, inflammation, metabolic and mitochondrial dysfunction, sleep and hormonal disruption, glutamatergic and oxidative stress — substantially produce depression by impairing plasticity, and the diverse effective treatments work by restoring it. Castrén's reframing sharpens the clinical implication: antidepressants may not directly improve mood but rather reopen a window of heightened, experience-dependent plasticity, which explains why combining medication with psychotherapy and environmental change so reliably outperforms medication alone — the drug renders the brain malleable; the life and the therapy determine what it becomes. The framework is not without limits — "plasticity" risks over-breadth, the human neurogenesis evidence is debated, and causality is incompletely resolved — but as the place where the many causes and the many treatments converge, the neuroplasticity hypothesis is the closest thing the field has to a unifying account of what depression is and how it lifts.

Selected references

1. Duman, R.S., & Monteggia, L.M. (2006). A neurotrophic model for stress-related mood disorders. Biological Psychiatry, 59(12), 1116–1127.
2. Castrén, E. (2005). Is mood chemistry? Nature Reviews Neuroscience, 6(3), 241–246.
3. Castrén, E., & Monteggia, L.M. (2021). Brain-derived neurotrophic factor signaling in depression and antidepressant action. Biological Psychiatry, 90(2), 128–136.
4. Santarelli, L., et al. (2003). Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science, 301(5634), 805–809.
5. Krishnan, V., & Nestler, E.J. (2008). The molecular neurobiology of depression. Nature, 455(7215), 894–902.
6. Duman, R.S., Aghajanian, G.K., Sanacora, G., & Krystal, J.H. (2016). Synaptic plasticity and depression: New insights from stress and rapid-acting antidepressants. Nature Medicine, 22(3), 238–249.
7. Pittenger, C., & Duman, R.S. (2008). Stress, depression, and neuroplasticity: A convergence of mechanisms. Neuropsychopharmacology, 33(1), 88–109.
8. McEwen, B.S., et al. (2015). Mechanisms of stress in the brain. Nature Neuroscience, 18(10), 1353–1363.
9. Sheline, Y.I., et al. (2003). Untreated depression and hippocampal volume loss. American Journal of Psychiatry, 160(8), 1516–1518.
10. Egan, M.F., et al. (2003). The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell, 112(2), 257–269.
11. Karege, F., et al. (2002). Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Research, 109(2), 143–148.
12. Li, N., et al. (2010). mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science, 329(5994), 959–964.
13. Sen, S., Duman, R., & Sanacora, G. (2008). Serum BDNF, depression and anti-depressant medications: Meta-analyses and implications. Biological Psychiatry, 64(6), 527–532.
14. Drevets, W.C., Price, J.L., & Furey, M.L. (2008). Brain structural and functional abnormalities in mood disorders. Brain Structure and Function, 213(1–2), 93–118.
15. Eisch, A.J., & Petrik, D. (2012). Depression and hippocampal neurogenesis: A road to remission? Science, 338(6103), 72–75.
16. Liu, B., et al. (2017). From serotonin to neuroplasticity: Evolvement of theories for major depressive disorder. Frontiers in Cellular Neuroscience, 11, 305.
17. Player, M.J., et al. (2013). Neuroplasticity in depressed individuals compared with healthy controls. Neuropsychopharmacology, 38(11), 2101–2108.
18. Boldrini, M., et al. (2018). Human hippocampal neurogenesis persists throughout aging. Cell Stem Cell, 22(4), 589–599. (And the contrasting Sorrells et al., 2018, Nature, on the neurogenesis debate.)
19. Hayley, S., & Litteljohn, D. (2013). Neuroplasticity and the next wave of antidepressant strategies. Frontiers in Cellular Neuroscience, 7, 218.
20. Olson, D.E. (2018). Psychoplastogens: A promising class of plasticity-promoting neurotherapeutics. Journal of Experimental Neuroscience, 12.